Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Surojit Sur

Showing results (11-20 of 24) with videos related to

Pageof 3
Sort By:
Iscience|June 13, 2022
An isogenic cell line panel for sequence-based screening of targeted anticancer drugsAshley L Cook, Nicolas Wyhs, Surojit Sur, et al.
Nature Communications|May 27, 2025
NXPE1 alters the sialoglycome by acetylating sialic acids in the human colonBum Seok Lee, Ashley Cook, Surojit Sur, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 4, 2012
Genetically defined subsets of human pancreatic cancer show unique in vitro chemosensitivityYunfeng Cui, Jacqueline A Brosnan, Amanda L Blackford, et al.
The American Journal of Pathology|November 9, 2013
Hypersensitivities for acetaldehyde and other agents among cancer cells null for clinically relevant Fanconi anemia genesSoma Ghosh, Surojit Sur, Sashidhar R Yerram, et al.
Elife|May 20, 2025
ME3BP-7 is a targeted cytotoxic agent that rapidly kills pancreatic cancer cells expressing high levels of monocarboxylate transporter MCT1Jordina Rincon-Torroella, Marco Dal Molin, Brian Mog, et al.
Biorxiv : the Preprint Server for Biology|August 7, 2023
ME3BP-7 is a targeted cytotoxic agent that rapidly kills pancreatic cancer cells expressing high levels of monocarboxylate transporter MCT1Jordina Rincon-Torroella, Marco Dal Molin, Brian Mog, et al.
Elife|February 17, 2025
Identification of nonsense-mediated decay inhibitors that alter the tumor immune landscapeAshley L Cook, Surojit Sur, Laura Dobbyn, et al.
Biorxiv : the Preprint Server for Biology|January 18, 2024
Identification of nonsense-mediated decay inhibitors that alter the tumor immune landscapeAshley L Cook, Surojit Sur, Laura Dobbyn, et al.
Nature Communications|January 3, 2023
The rapid and highly parallel identification of antibodies with defined biological activities by SLISYSteve Lu, Austin K Mattox, P Aitana Azurmendi, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 19, 2014
Systemic delivery of microencapsulated 3-bromopyruvate for the therapy of pancreatic cancerJulius Chapiro, Surojit Sur, Lynn Jeanette Savic, et al.
Pageof 3

Showing results (11-20 of 24) with videos related to

Sort By:
Pageof 3
Iscience|June 13, 2022
An isogenic cell line panel for sequence-based screening of targeted anticancer drugsAshley L Cook, Nicolas Wyhs, Surojit Sur, et al.
Nature Communications|May 27, 2025
NXPE1 alters the sialoglycome by acetylating sialic acids in the human colonBum Seok Lee, Ashley Cook, Surojit Sur, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 4, 2012
Genetically defined subsets of human pancreatic cancer show unique in vitro chemosensitivityYunfeng Cui, Jacqueline A Brosnan, Amanda L Blackford, et al.
The American Journal of Pathology|November 9, 2013
Hypersensitivities for acetaldehyde and other agents among cancer cells null for clinically relevant Fanconi anemia genesSoma Ghosh, Surojit Sur, Sashidhar R Yerram, et al.
Elife|May 20, 2025
ME3BP-7 is a targeted cytotoxic agent that rapidly kills pancreatic cancer cells expressing high levels of monocarboxylate transporter MCT1Jordina Rincon-Torroella, Marco Dal Molin, Brian Mog, et al.
Biorxiv : the Preprint Server for Biology|August 7, 2023
ME3BP-7 is a targeted cytotoxic agent that rapidly kills pancreatic cancer cells expressing high levels of monocarboxylate transporter MCT1Jordina Rincon-Torroella, Marco Dal Molin, Brian Mog, et al.
Elife|February 17, 2025
Identification of nonsense-mediated decay inhibitors that alter the tumor immune landscapeAshley L Cook, Surojit Sur, Laura Dobbyn, et al.
Biorxiv : the Preprint Server for Biology|January 18, 2024
Identification of nonsense-mediated decay inhibitors that alter the tumor immune landscapeAshley L Cook, Surojit Sur, Laura Dobbyn, et al.
Nature Communications|January 3, 2023
The rapid and highly parallel identification of antibodies with defined biological activities by SLISYSteve Lu, Austin K Mattox, P Aitana Azurmendi, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 19, 2014
Systemic delivery of microencapsulated 3-bromopyruvate for the therapy of pancreatic cancerJulius Chapiro, Surojit Sur, Lynn Jeanette Savic, et al.
Pageof 3